Ken Griffin Citadel Advisors
Ken Griffin founded Citadel, one of the world’s largest and most successful hedge funds. Starting his trading career from his Harvard dorm room at a young age, Griffin quickly developed a keen sense for markets and built Citadel into a global powerhouse with billions in assets under management. Known for his quantitative and technology-driven strategies, Griffin has also made headlines for significant philanthropic contributions, supporting causes in education, the arts, and public institutions. Over the years, he has earned recognition as one of the preeminent figures in modern finance.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Meta Platforms (Facebook)
META
|
+$772M |
| 2 |
Eli Lilly
LLY
|
+$337M |
| 3 |
lululemon athletica
LULU
|
+$301M |
| 4 |
iShares iBoxx $ High Yield Corporate Bond ETF
HYG
|
+$297M |
| 5 |
ResMed
RMD
|
+$273M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$576M |
| 2 |
AT&T
T
|
+$476M |
| 3 |
PNC Financial Services
PNC
|
+$393M |
| 4 |
Fortive
FTV
|
+$389M |
| 5 |
Accenture
ACN
|
+$374M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 2.83% |
| 2 | Technology | 2.79% |
| 3 | Financials | 2.29% |
| 4 | Consumer Discretionary | 1.93% |
| 5 | Industrials | 1.63% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
4176
Banco Macro
BMA
$4.96B
| $3.87M | ﹤0.01% |
345,380
+210,103
| +155% | +$3.12M |
|
|
RAD
4177
CALL
DELISTED
Rite Aid Corporation
RAD
| $3.87M | ﹤0.01% |
573,800
+398,300
| +227% | +$2.64M |
|
4178
CALL
Masco
MAS
$14.7B
| $3.87M | ﹤0.01% |
76,400
-16,400
| -18% | -$867K |
|
|
CTEV
4179
Claritev Corp
CTEV
$646M
| $3.87M | ﹤0.01% |
17,600
+10,626
| +152% | +$2.1M |
|
4180
CALL
Invitation Homes
INVH
$18B
| $3.86M | ﹤0.01% |
108,600
+1,300
| +1% | +$49.6K |
|
4181
CALL
Global X Silver Miners ETF NEW
SIL
$4.79B
| $3.86M | ﹤0.01% |
149,200
+9,200
| +7% | +$295K |
|
|
CBAY
4182
DELISTED
Cymabay Therapeutics
CBAY
| $3.86M | ﹤0.01% |
1,309,877
+343,000
| +35% | +$819K |
|
4183
CALL
Vanguard Health Care ETF
VHT
$18.9B
| $3.86M | ﹤0.01% |
16,400
-6,700
| -29% | -$1.61M |
|
4184
CALL
Revolve Group
RVLV
$1.68B
| $3.86M | ﹤0.01% |
149,000
+61,900
| +71% | +$2.29M |
|
|
AEAC
4185
DELISTED
Authentic Equity Acquisition Corp. Class A ordinary share
AEAC
| $3.86M | ﹤0.01% |
391,978
-399,584
| -50% | -$3.93M |
|
4186
CALL
Jackson Financial
JXN
$9.17B
| $3.86M | ﹤0.01% |
144,300
+54,500
| +61% | +$1.99M |
|
4187
Primoris Services
PRIM
$4.48B
| $3.86M | ﹤0.01% |
177,390
+46,547
| +36% | +$1.12M |
|
4188
e.l.f. Beauty
ELF
$5.4B
| $3.86M | ﹤0.01% |
125,742
-51,427
| -29% | -$1.29M |
|
|
AAN
4189
DELISTED
The Aaron's Company Inc
AAN
| $3.86M | ﹤0.01% |
265,132
+227,756
| +609% | +$4.35M |
|
4190
Stepan Co
SCL
$1.48B
| $3.86M | ﹤0.01% |
38,060
+29,766
| +359% | +$3.08M |
|
4191
PUT
PubMatic
PUBM
$801M
| $3.85M | ﹤0.01% |
242,600
-28,400
| -10% | -$608K |
|
4192
Janus Henderson Short Duration Income ETF
VNLA
$3.36B
| $3.85M | ﹤0.01% |
79,206
-34,708
| -30% | -$1.69M |
|
4193
Core Laboratories
CLB
$571M
| $3.85M | ﹤0.01% |
194,407
+109,255
| +128% | +$2.9M |
|
4194
PUT
Gilat Satellite Networks
GILT
$887M
| $3.85M | ﹤0.01% |
637,300
+122,700
| +24% | +$858K |
|
4195
Magnolia Oil & Gas
MGY
$6.22B
| $3.85M | ﹤0.01% |
183,286
-133,927
| -42% | -$3.35M |
|
4196
ProShares Ultra QQQ
QLD
$14.4B
| $3.85M | ﹤0.01% |
+185,746
| New | +$4.85M |
|
4197
Revolution Medicines
RVMD
$43.7B
| $3.84M | ﹤0.01% |
197,060
+130,258
| +195% | +$2.54M |
|
|
NVTA
4198
DELISTED
Invitae Corporation
NVTA
| $3.84M | ﹤0.01% |
1,574,269
-1,297,498
| -45% | -$5.74M |
|
4199
Brookfield Infrastructure Partners
BIP
$18.3B
| $3.84M | ﹤0.01% |
100,436
-7,611
| -7% | -$313K |
|
4200
PUT
iShares US Aerospace & Defense ETF
ITA
$15.1B
| $3.83M | ﹤0.01% |
38,600
-113,700
| -75% | -$11.7M |
|
Similar funds
Ken Griffin's Q2 2022 Portfolio in Review
As of Q2 2022, Ken Griffin held 14,957 positions worth $390B, down 20% from $484B the previous quarter. Its ten largest holdings account for 28% of the portfolio.
Ken Griffin's Q2 2022 filing shows 1,520 new, 5,503 increased, 5,522 reduced and 2,191 closed positions. Its largest new stake was ResMed: 1,280,595 shares worth $268M. The largest sale was State Street SPDR S&P 500 ETF Trust, an estimated $576M.
By sector, the portfolio is most concentrated in Healthcare at 2.8% of assets, up from 2.4% a quarter earlier, followed by Technology and Financials.
- Ken Griffin's largest Q2 2022 buy was ResMed: 1,280,595 shares worth $268M.
- Ken Griffin added most to Meta Platforms (Facebook) in Q2 2022, an estimated $772M increase.
- Ken Griffin's biggest Q2 2022 reduction was State Street SPDR S&P 500 ETF Trust, cutting an estimated $576M.
- Ken Griffin fully exited Vanguard Morningstar Small-Cap ETF in Q2 2022, selling an estimated $184M.
- Ken Griffin's ten largest holdings make up 28% of its $390B portfolio in Q2 2022.
- Ken Griffin opened 1,520 new positions and closed 2,191 in Q2 2022.
- Ken Griffin's portfolio value fell 20% quarter-over-quarter to $390B.
Based on Citadel Advisors's 13F filing for Q2 2022, filed 15 Aug 2022.